A comparison of prostate cancer treatments: are therapeutic implications justified?
作者信息
Scardino P T, Hanks G E
机构信息
Baylor College of Medicine, Houston, Texas, USA.
出版信息
Cancer J Sci Am. 1997 Mar-Apr;3(2):70-2.
PMID:9099454
Abstract
摘要
相似文献
1
A comparison of prostate cancer treatments: are therapeutic implications justified?前列腺癌治疗方法的比较：治疗意义是否合理？
Cancer J Sci Am. 1997 Mar-Apr;3(2):70-2.
2
Short- and long-term mortality with localized prostate cancer.局限性前列腺癌的短期和长期死亡率
Arch Intern Med. 2007 Oct 8;167(18):1944-50. doi: 10.1001/archinte.167.18.1944.
3
Re: Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.关于：嗜铬粒蛋白A浓度作为预测前列腺癌内分泌治疗后预后的血清标志物
J Urol. 2003 Jun;169(6):2305; author reply 2305. doi: 10.1097/01.ju.0000065590.46394.1d.
4
Prostate cancer: metastatic.
Clin Evid. 2002 Jun(7):804-11.
5
Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916.体重指数与转移性前列腺癌男性患者的反应及生存情况的关联：西南肿瘤协作组8894和9916试验
J Urol. 2007 Nov;178(5):1946-51; discussion 1951. doi: 10.1016/j.juro.2007.07.026. Epub 2007 Sep 17.
6
Contemporary view of prostate cancer diagnosis and treatment.
Aust Fam Physician. 2003 Jun;32(6):396-8.
7
Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.前列腺特异性抗原（PSA）作为前列腺癌临床试验中生存的替代终点。
Eur Urol. 2008 Jan;53(1):6-9. doi: 10.1016/j.eururo.2007.08.041. Epub 2007 Aug 28.
8
Deferred treatment in localized prostatic cancer.局限性前列腺癌的延迟治疗
Prog Clin Biol Res. 1990;359:191-7; discussion 223-9.
9
Prostate biopsy: who, how and when. An update.前列腺活检：对象、方法及时机。最新进展。
Can J Urol. 2005 Feb;12 Suppl 1:44-8; discussion 99-100.
10
The search for better prognostic factors for men treated for localized prostate cancer continues.针对接受局限性前列腺癌治疗的男性，寻找更好的预后因素的工作仍在继续。
Eur Urol. 2008 Apr;53(4):689-90. doi: 10.1016/j.eururo.2007.12.009. Epub 2007 Dec 17.
Zotero 插件